Skip to main content
HairCited

低出力レーザー治療 男性型・女性型脱毛症(AGA)

A

合計11,100名の参加者を対象とした58件の研究(メタアナリシス7件、RCT 8件を含む)に基づく。58件中49件の研究で肯定的な効果が示されている。

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dlow\u002Dlevel\u002Dlaser\u0026condition\u003Dandrogenetic\u002Dalopecia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

結論

Low-level laser therapy has strong, well-established evidence for supporting hair growth in androgenetic alopecia, backed by multiple meta-analyses and randomized controlled trials.

  • 49 out of 58 studies show positive effects, supported by 7 meta-analyses and 8 RCTs
  • Stimulates hair follicles through photobiomodulation at specific light wavelengths
  • Included in clinical guidelines as an evidence-based option for pattern hair loss
  • Available as at-home devices (caps, combs, helmets) and clinical in-office systems

Key Study Findings

review
The Use of Light-Based Therapies in the Treatment of Alopecia.
Dose: Low-level light therapy (LLLT) various devices and wavelengths; combined with minoxidil or finasteri vs: Placebo 効果: LLLT improves hair density in AGA; potential to prolong anagen phase in telogen effluvium; may promo None
other n=723
Consensus Recommendations for the Management of Androgenetic Alopecia in Egypt: A Modified Delphi Study.
Dose: None vs: Placebo 効果: 27 consensus statements established across 7 areas: diagnosis, minoxidil, antiandrogens, LLLT, adjuv None
systematic review
Full-Spectrum phototherapy in hair loss management: a systematic review of wavelength-dependent mechanisms, clinical efficacy, and …
Dose: Full-spectrum phototherapy: UVB/UVA, red light, near-infrared (short and long wavelength), mid-infra vs: Placebo 効果: UVB/UVA induces T-cell apoptosis (restoring immune privilege in AA); red light activates mitochondri None
review
The role of microtrauma in hair regrowth and regeneration in non-scarring alopecia.
Dose: Various microtrauma procedures: microneedling, fractional/non-fractional lasers, contact immunothera vs: Placebo 効果: Positive outcomes reported for hair density and thickness with microneedling, lasers, LLLT, and PRP None
randomized controlled trial n=9 12.5 weeks Single-blind
Photobiomodulation therapy and 5% minoxidil in female pattern hair loss: a case series focusing on …
Dose: Photobiomodulation therapy (PBMt; red laser 100mW, 4J/point, 25 sessions, twice weekly) + minoxidil vs: Placebo 効果: Both groups improved QoL and hair density; PBMt + MIN showed significantly greater reduction in telo None

Key Statistics

60

研究数

11100

参加者数

Positive

A

グレード

Referenced Papers

Journal of cutaneous … 2025 2 件の引用
Lasers in medical … 2025 1 件の引用
International journal of … 2024 39 件の引用
Journal of clinical … 2024 10 件の引用
Facial plastic surgery … 2024 8 件の引用
Revue medicale suisse 2024 2 件の引用
Clinical, cosmetic and … 2023 58 件の引用
American journal of … 2023 41 件の引用
Clinics in plastic … 2023 1 件の引用
Dermatology and therapy 2022 43 件の引用
Journal of cutaneous … 2021 44 件の引用
Actas dermo-sifiliograficas 2021 3 件の引用
Expert opinion on … 2020 147 件の引用
Dermatologic therapy 2020 48 件の引用
Acta dermatovenerologica Alpina, … 2019 7 件の引用
Lasers in medical … 2018 75 件の引用
Lasers in surgery … 2017 71 件の引用
Actas dermo-sifiliograficas 2017 17 件の引用
The Cochrane database … 2016 18 件の引用
Lasers in surgery … 2014 243 件の引用
Facial plastic surgery … 2013 16 件の引用

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

hairloss:
8-15 minutes, 3x/week

上限量: Not applicable

研究で検討された用量

用量 期間 効果 N
None -- Positive --
Low-level light therapy (LLLT) various devices and wavelengths; combined with minoxidil or finasteri -- Positive --
None -- Neutral 723
Full-spectrum phototherapy: UVB/UVA, red light, near-infrared (short and long wavelength), mid-infra -- Positive --
Various microtrauma procedures: microneedling, fractional/non-fractional lasers, contact immunothera -- Positive --
Photobiomodulation therapy (PBMt; red laser 100mW, 4J/point, 25 sessions, twice weekly) + minoxidil 12.5 weeks Positive 9
Low-level laser therapy (LLLT) combined with topical minoxidil vs topical minoxidil alone -- Positive --
None -- Positive --

推奨摂取タイミング: Use device for recommended duration 3 times per week on non-consecutive days

Safety & Side Effects

報告されている副作用

  • Mild scalp warmth or tingling
  • Headache (uncommon)
  • Initial shedding phase (rare)
  • Dry scalp

既知の相互作用

  • Photosensitizing medications (tetracyclines, fluoroquinolones) may increase scalp sensitivity
  • No significant interactions with oral hair loss medications

耐容上限摂取量: Not applicable

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does 低出力レーザー治療 help with 男性型・女性型脱毛症(AGA)?
Based on 60 studies with 11,100 participants, there is strong evidence from multiple clinical trials that 低出力レーザー治療 may support 男性型・女性型脱毛症(AGA) management. Our evidence grade is A (Strong Evidence).
How much 低出力レーザー治療 should I take for 男性型・女性型脱毛症(AGA)?
Studies have used various dosages. A commonly studied range is 8-15 minutes, 3x/week. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 低出力レーザー治療?
Reported side effects may include Mild scalp warmth or tingling, Headache (uncommon), Initial shedding phase (rare), Dry scalp. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 低出力レーザー治療 and 男性型・女性型脱毛症(AGA)?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 60 peer-reviewed studies with 11,100 total participants. The overall direction of effect is positive.

Related Evidence

低出力レーザー治療 他の症状・状態について

FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。